Compare DexCom, Inc. (DXCM) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? DexCom, Inc. trades at $83.67 (market cap $31.86B), while Charles Schwab Corporation Common Stock trades at $97.09 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 5.3× DexCom, Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| DXCM | SCHW | |
|---|---|---|
Market Cap | $31.86B | $167.52B |
Volume | 3,607,070 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $92.34 | $113.65 |
52-Week Low | $54.84 | $85.35 |
Typical Hold Time | 62 Days | 85 Days |
Enterprise Value | $31.32B | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Charles Schwab (SCHW) trades at $96.80, up 1.28% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 17.64, net income margin of 38.79%, and robust cash flow. Recent news highlights growth in client assets to $13.41 trillion and a strategic AI partnership with Anthropic.
The outlook is positive with a consensus price target of $120.33, implying significant upside. Risks include competitive pressures and market volatility, but strong earnings momentum and a favorable industry growth forecast support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
